News
-
DSM Announces Biologics Development And Manufacturing Agreement For Australian Facility
10/24/2012
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed a biologics contract manufacturing agreement with Paranta Biosciences Ltd of Melbourne , Australia.
-
AMRI Announces Five-Year Extension Of API Supply Agreement With Shire
10/18/2012
AMRI (NASDAQ: AMRI) announced today that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing Inc., whose parent company, Shire plc (LSE: SHP, NASDAQ: SHPGY), is a global company that focuses its business on behavioral health, gastro intestinal diseases, rare diseases and regenerative medicine.
-
SAGE® Labs, Ekam Imaging, Inc. Partner To Develop Preclinical Imaging Assays To Screen Therapies Of Neurodegenerative Disease
10/16/2012
Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma Advanced Genetic Engineering (SAGE) Labs, an initiative of Sigma®Life Science, and Ekam Imaging, Inc. have partnered to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology. For more information on SAGE Labs, visit www.sageresearchmodels.com
-
Aptalis Pharmaceutical Technologies Sponsors AAPS Research Achievement Awards In Pharmacokinetics, Pharmacodynamics And Drug Metabolism At AAPS Annual Meeting And Exposition
10/11/2012
Aptalis Pharmaceutical Technologies, formerly Eurand, focused on developing differentiated oral products utilizing its pharmaceutical technologies, recently announces its sponsorship of the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Awards in Pharmacokinetics, Pharmacodynamics and Drug Metabolism and its participation in the 2012 AAPS Annual Meeting and Exposition October 14 – 18, 2012 in Chicago, Illinois.